Acadian Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Acadian Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-883	Closed	-$38K	–	1864
2023 Q3	$38K	Buy	883 +386	+78%	+$13.8K	﹤0.01%	1460
2023 Q2	$17K	Buy	+497	New	+$20.5K	﹤0.01%	1658
2023 Q1	–	Sell	-2,300	Closed	-$102K	–	2027
2022 Q4	$102K	Buy	+2,300	New	+$149K	﹤0.01%	1427
2022 Q3	–	Sell	-10,448	Closed	-$701K	–	1903
2022 Q2	$701K	Buy	10,448 +8,124	+350%	+$517K	﹤0.01%	892
2022 Q1	$189K	Buy	+2,324	New	+$238K	﹤0.01%	1228
2018 Q2	–	Sell	-547	Closed	-$17K	–	1887
2018 Q1	$17K	Buy	+547	New	+$15.2K	﹤0.01%	1508

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Acadian Asset Management's MRTX Position: Q4 2023 in Review

Acadian Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 883 shares — an estimated $38K sold.

Acadian Asset Management first reported a position in MRTX in Q1 2018 and held it in 6 quarters. The position peaked at $701K in Q2 2022. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Acadian Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Acadian Asset Management sold 883 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $38K.
Acadian Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 6 quarters.
Acadian Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $701K in Q2 2022.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Acadian Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.